Publication:
Diabetes, mortality and glucose monitoring rates in the TREAT Asia HIV Observational Database Low Intensity Transfer (TAHOD-LITE) study

dc.contributor.authorR. Bijkeren_US
dc.contributor.authorN. Kumarasamyen_US
dc.contributor.authorS. Kiertiburanakulen_US
dc.contributor.authorS. Pujarien_US
dc.contributor.authorL. Penh Sunen_US
dc.contributor.authorO. T. Ngen_US
dc.contributor.authorM. P. Leeen_US
dc.contributor.authorJ. Y. Choien_US
dc.contributor.authorK. V. Nguyenen_US
dc.contributor.authorY. J. Chanen_US
dc.contributor.authorT. P. Meratien_US
dc.contributor.authorC. D. Doen_US
dc.contributor.authorJ. Rossen_US
dc.contributor.authorM. Lawen_US
dc.contributor.authorP. S. Lyen_US
dc.contributor.authorV. Kholen_US
dc.contributor.authorP. C.K. Lien_US
dc.contributor.authorW. Lamen_US
dc.contributor.authorY. T. Chanen_US
dc.contributor.authorS. Saghayamen_US
dc.contributor.authorC. Ezhilarasien_US
dc.contributor.authorK. Joshien_US
dc.contributor.authorS. Gaikwaden_US
dc.contributor.authorA. Chitalikaren_US
dc.contributor.authorD. N. Wirawanen_US
dc.contributor.authorF. Yulianaen_US
dc.contributor.authorP. L. Limen_US
dc.contributor.authorL. S. Leeen_US
dc.contributor.authorZ. Ferdousen_US
dc.contributor.authorS. Naen_US
dc.contributor.authorJ. M. Kimen_US
dc.contributor.authorW. W. Wongen_US
dc.contributor.authorW. W. Kuen_US
dc.contributor.authorP. C. Wuen_US
dc.contributor.authorA. V. Ngoen_US
dc.contributor.authorL. T. Nguyenen_US
dc.contributor.authorH. V. Buien_US
dc.contributor.authorD. T.H. Nguyenen_US
dc.contributor.authorD. T. Nguyenen_US
dc.contributor.authorA. H. Sohnen_US
dc.contributor.authorJ. L. Rossen_US
dc.contributor.authorB. Petersenen_US
dc.contributor.authorA. Jiamsakulen_US
dc.contributor.authorD. Rupasingheen_US
dc.contributor.authorM. G. Lawen_US
dc.contributor.otherThe Voluntary Health Services, Chennaien_US
dc.contributor.otherBach Mai Hospitalen_US
dc.contributor.otherUniversitas Udayanaen_US
dc.contributor.otherKirby Instituteen_US
dc.contributor.otherYonsei University College of Medicineen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherQueen Elizabeth Hospital Hong Kongen_US
dc.contributor.otherVeterans General Hospital-Taipeien_US
dc.contributor.otherTan Tock Seng Hospitalen_US
dc.contributor.otherUniversity of Health Sciencesen_US
dc.contributor.otherNational Hospital for Tropical Diseasesen_US
dc.contributor.otherFoundation for AIDS Researchen_US
dc.contributor.otherInstitute of Infectious Diseasesen_US
dc.date.accessioned2020-01-27T09:29:38Z
dc.date.available2020-01-27T09:29:38Z
dc.date.issued2019-10-01en_US
dc.description.abstract© 2019 British HIV Association Objectives: Diabetes is a growing cause of morbidity and mortality in people living with HIV (PLHIV) receiving antiretroviral therapy (ART). We investigated the association between fasting plasma glucose (FPG) levels and mortality, and factors associated with FPG monitoring rates in Asia. Methods: Patients from the Therapeutics Research, Education, and AIDS Training in Asia (TREAT Asia) HIV Observational Database Low Intensity Transfer (TAHOD-LITE) cohort were included in the present study if they had initiated ART. Competing risk and Poisson regression were used to analyse the association between FPG and mortality, and assess risk factors for FPG monitoring rates, respectively. FPG was categorized as diabetes (FPG ≥ 7.0 mmol/L), prediabetes (FPG 5.6–6.9 mmol/L) and normal FPG (FPG ' 5.6 mmol/L). Results: In total, 33 232 patients were included in the analysis. Throughout follow-up, 59% had no FPG test available. The incidence rate for diabetes was 13.7 per 1000 person-years in the 4649 patients with normal FPG at ART initiation. Prediabetes [sub-hazard ratio (sHR) 1.32; 95% confidence interval (CI) 1.07–1.64] and diabetes (sHR 1.90; 95% CI 1.52–2.38) were associated with mortality compared to those with normal FPG. FPG monitoring increased from 0.34 to 0.78 tests per person-year from 2012 to 2016 (P ' 0.001). Male sex [incidence rate ratio (IRR) 1.08; 95% CI 1.03–1.12], age ' 50 years (IRR 1.14; 95% CI 1.09–1.19) compared to ≤ 40 years, and CD4 count ≥ 500 cells/μL (IRR 1.04; 95% CI 1.00–1.09) compared to ' 200 cells/μL were associated with increased FPG monitoring. Conclusions: Diabetes and prediabetes were associated with mortality. FPG monitoring increased over time; however, less than half of our cohort had been tested. Greater resources should be allocated to FPG monitoring for early diabetic treatment and intervention and to optimize survival.en_US
dc.identifier.citationHIV Medicine. Vol.20, No.9 (2019), 615-623en_US
dc.identifier.doi10.1111/hiv.12779en_US
dc.identifier.issn14681293en_US
dc.identifier.issn14642662en_US
dc.identifier.other2-s2.0-85069869768en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/51404
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85069869768&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleDiabetes, mortality and glucose monitoring rates in the TREAT Asia HIV Observational Database Low Intensity Transfer (TAHOD-LITE) studyen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85069869768&origin=inwarden_US

Files

Collections